Asian Retina Programme Virtual 2021 - ASIAN RETINA Thurs. 25 March - OPHTHALMOLOGY ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
ASIAN RETINA
Thurs. 25 March
ednesday 30 September
Asian Retina Programme
Virtual 2021
Vision, a window to the world.
With vision, we connect with others.
With vision, we feel happiness.
That is why we at Santen believe
seeing is integral to life.
As a company focused on vision,
we explore and grow the unlimited potential
of our ability to see.
Because we know we can one day
achieve a world free of vision problems.
Because we know we can one day
create a future full of smiles
where everyone’s vision is nurtured.
Until then, we will not stop challenging ourselves.
ASIAN RETINA VIRTUAL FORUM 2021 1
CONTENTS:
RETINA PROGRAMME
Welcome 3
Timings 4
Speakers
Presenting companies | Pannelists | Chairs 6
Our sponsors 7
Platinum 8
Gold 9
Silver 10
Bronze 11
New innovator 12
Save the date 2021 13
Programme committee 14
ASIAN RETINA VIRTUAL FORUM 2021 2
WELCOME:
RETINA VIRTUAL FORUM
Dear colleagues,
Welcome to the Ophthalmology Futures Asian Highlights include sessions on: myopia, surgical
Retina Forum 2021. The virtual format for this robotics, imaging, telemedicine, gene therapy
year's forum has presented us with challenges and real world pharmacologic treatment of
and opportunities. While missing the chance posterior segment diseases. There will also be a
to network with participants in person, we region focused panel discussion on investment
are able to reach a much larger audience and for diagnostic and therapeutic modalities aimed
include speakers who would otherwise not have at reducing the burden of retinal diseases.
been able to make the trip to Asia for an in
Ophthalmology Futures Forums would like to
person meeting.
thank our key advisors, corporate presenters
The unique nature of innovation relating to and distinguished faculty for their invaluable
diseases of the posterior segment led us to support and assistance. We would also like
recognize the need for a standalone Retina to especially thank our sponsors who have
Forum to increase our focus in this rapidly provided support allowing us to have this
evolving space a few years ago and we have meeting without a registration fee for all
been delighted by the success of this format. attendees!
As in prior Retina Forums, we will have Thank you for joining us!
presentations from companies at various stages
Keith Barton and Kuldev Singh
of the innovation process and panels on topics
on behalf of the Ophthalmology Futures Team
deemed to be of interest to all stakeholders.
Ophthalmology Futures is dedicated to creating
a novel program for each forum and this forum
will, in particular, focus on issues deemed
relevant to retina practice in Asia.
Vision Futures Limited, London, UK.
Registered in England No: 8125858.
ASIAN RETINA VIRTUAL FORUM 2021 3
TIMINGS:
RETINA VIRTUAL FORUM
08:00 - 08:10 11:40 - 12:10
WELCOME FROM THE PANEL 4: ACCESS TO MODERN
CO-CHAIRS RETINA SURGERY IN ASIA:
IS IT IMPROVING?
Co-chairs
• Keith Barton Chair
• Kuldev Singh • Shu Yen Lee
Panellists
• Hai Lu
08:10 - 08:40 • Kazuaki Kadonosono
PANEL 1: IS MYOPIA • Kim Ramasamy
PREVENTION A VIABLE • Paul Hallen
BUSINESS OPPORTUNITY? • Steve Charles
• Woohyok Chang
Chair
• Marcus Ang
Panellists 12:10 - 12:40
• Kyoko Ohno Matsui
• Noel Brennan
PANEL 5: INNOVATION IN
IMAGING AND TELEMEDICINE
• Olga Prenat
TO IMPROVE REMOTE ACCESS
• Pei Chang Wu
TO OPHTHALMIC CARE
• Reza Haque
• Seang Mei Saw Co-chairs
• Xiang Tian Zhou • Paisan Ruamviboonsuk
• Tien Yin Wong
Panellists
08:40 - 09:30 • Almira Chabi
COMPANY PRESENTATIONS 1 • Joe Redner
• Kester Nahen
Companies • Mingguang He
• AVECRIS Pte Ltd. | Volker Patzel • Ryan Bouchard
• GenSight Biologics | Magali Taiel • Xiaoyan Ding
• Adverum Biotechnologies | Aaron Osborne
• Isarna Therapeutics | Marion Munk
• Iveric Bio | Pravin Dugel 12:40 - 13:30
COMPANY PRESENTATIONS 3
09:30 - 10:00 • Notal Vision Inc. | Kester Nahen
• Risk Medical Solutions | Sigurbjörg Ásta Jónsdóttir
PANEL 2: REAL WORLD
• NovaSight | Ran Yam
ANTI-VEGF UTILISATION IN
ASIA AND THE OPPORTUNITY • Samsara Vision | Thomas Ruggia
FOR GENE THERAPY • Norlase | Oliver Hvidt
• Preceyes | Marc De Smet
Co-chairs
• Adnan Tufail
• Timothy Lai 13:30 - 14:00
Panellists
PANEL 6: REDUCING THE
• Abu Abraham
UNMET NEED FOR CARE
• Chris Brittain
IN ASIA: SURGICAL ROBOTICS
• Dirk Sauer
& SMART IMPLANTS
• Gemmy Cheung
• Keith Lane Chair
• Pravin Dugel • Steve Charles
• Steve Pakola Panellists
• Luis Diaz-Santana
• Paul Hallen
10:00 - 10:40 • Vivek Dave
• Xiaorong Li
PANEL 3: INVESTMENT
UPDATE & PANEL DISCUSSION
Chair 14:00 - 14:10
• Michael Keyoung
SUMMARY
Panellists
• Ali Behbahani • Adnan Tufail
• Amit Kakar
• Cynthia Bai
• Dennis Lam 14:10 - 14:15
• Malcolm Ngiam CONCLUDING REMARKS
FROM THE CO-CHAIRS
Co-chairs
10:40 - 11:30 • Keith Barton
COMPANY PRESENTATIONS 2 • Kuldev Singh
• RE-VANA THERAPEUTICS | Michael O’Rourke
• AsclepiX Therapeutics, Inc. | Theresa Heah
• Ocuphire Pharma | Mina Sooch
• OcuTerra Therapeutics | Kerrie Brady
11:30 - 11:40
SPONSOR SHOWCASE
ASIAN RETINA VIRTUAL FORUM 2021 4
VISUAL FREEDOM IN ONE EXCEPTIONAL LENS
ASTIGMATISM
MYOPIA
The Visian Toric ICL clinical trial reported 1:
• 98.4% of patients would have the Visian Toric ICL procedure again
• Predictable outcomes realized across a broad range of treatment options
• 93.8% of eyes maintained or gained 1 or more lines of BSCVA
• Rapid and stable achievement of outstanding MRSE and MRCyl
• In eyes with pre-op BSCVA 20/20 or better 100% of eyes obtained 20/40 or better UCVA
• Over 94% of eyes maintained rotational stability of ≤ 5˚ at all post - op time points
1 STAAR Surgical Visian Toric Implantable Collamer Lens PMA Supplement P030016 Ophthalmic Devices Advisory Panel, March 14, 2014
SPEAKERS: PRESENTING COMPANIES
PANNELISTS & CHAIRS
CHAIRS & PANELLISTS PRESENTING
COMPANIES
A O
• Abu Abraham • Olga Prenat
VP, Retina Therapeutic Area Global Director, Education & A
Strategy, Santen Professional Relations, Essilor
• Adverum Biotechnologies
• Adnan Tufail International
Aaron Osbourne, CMO
Consultant Ophthalmic
• AsclepiX Therapeutics, Inc.
Surgeon, Moorfields Eye
Theresa Heah, CMO
Hospital NHS Trust, London,
UK P • AVECRIS Pte Ltd.
• Paisan Ruamviboonsuk Volker Patzel, Founder
• Ali Behbahan
General Partner, New Clinical Professor, Department
Enterprise Associates of Ophthalmology, Rajavithi
Hospital, Bangkok, Thailand
• Almira Chabi
• Paul Hallen
G
VP, Glaucoma &
Neuroprotection, Santen VP, Global Head Retina, Alcon • GenSight Biologics
Magali Taiel, CMO
• Amit Kakar • Pei Chang Wu
Senior Partner, Head of Novo Professor & Director, Myopia
Holdings Asia Prevention & Treatment
Center, Department of
Ophthalmology, Kaohsiung
I
Chang Gung Memorial • Isarna Therapeutics
C Hospital, Taiwan Marion Munk, CEO
• Christopher Brittain • Pravin Dugel • Iveric Bio
VP, Global Head of Executive VP, Chief Business & Pravin Dugel, CBO
Ophthalmology Product Strategy Officer, Iveric Bio
Development, Genetech • Prof Hai Lu MD,
Vice Chair of Department
• Cynthia Bai
CMO, Rimonci Capital of Ophthalmology, Beijing N
Tongren Hosptial, Capital
• Norlase
University of Medical Science,
Oliver Hvidt, CEO
China
D • Notal Vision Inc.
Kester Nahen, CEO
• Dennis Lam • NovaSight
Director, C-MER International R Ran Yam, CEO
Eye Care Group
• Reza Haque
• Dirk Sauer Senior VP & Global Head
Global Development Unit
Head, Ophthalmology Unit,
Ophthalmic Innovation Center,
Santen
O
Novartis Pharma AG
• Ryan Bouchard • Ocuphire Pharma
VP, Medical Devices, Ora, Inc. Mina Sooch, CEO
• OcuTerra Therapeutics
G Kerrie Brady, CEO
• Gemmy Cheung Chui Ming S
Consultant Ophthalmologist,
Singapore National Eye Center • Seang Mei Saw
SERI Professor of
P
Ophthalmology Research, • Preceyes
Duke-NUS Medical School Marc De Smet, CMO
J & Singapore Eye Research
Institute
• Joe Redner
• Shu Yen Lee
Head of ZEISS Australia & New
Senior Consultant & Head, R
Zealand, Head of APAC Sales/
Surgical Retina, Singapore
Ophthalmic Devices, Medical • RE-VANA THERAPEUTICS
National Eye Centre. Clinical
Technology Business Group Michael O’Rourke, CEO
Director, Retina Centre,
Diabetes & Metabolism Centre, • Risk Medical Solutions
Singapore General Hospital, Sigurbjörg Ásta Jónsdóttir, CEO
K •
Singapore
Stephen Pakola
• Kazuaki Kadonosono
Professor & Chair Yokohama
CMO, REGENXBIO Inc
S
• Steve Charles
City University, Japan • Samsara Vision
CEO & Founder, Charles Retina
• Keith Lane Institute & Clinical Professor of Thomas Ruggia, CEO
Vice President, Posterior Ophthalmology, University of
Segment department, Ora Tennessee, USA
Clinical
• Kester Nahen
CEO, Notal Vision Ltd.
• Kim Ramasamy
T ALL OF THE SPEAKERS FOR
CMO & Senior Retina • Tien Yin Wong
Consultant, Aravind Eye
THE ASIAN RETINA AND ASIAN
Arthur Lim Professor of
Hospital, Madurai, India Ophthalmology, Medical FORUMS CAN BE FOUND ON
• Kyoko Ohno Matsui Director, Singapore National OUR WEBSITE:
Professor & Chairperson, Eye Centre. Chairman,
Department of Ophthalmology Singapore Eye Research OPHTHALMOLOGY-
& Visual Science, Tokyo Institute, Vice Dean, Duke-
NUS Medical School, National FUTURES.COM/FORUMS
Medical & Dental University,
Japan University of Singapore
• Timothy Lai
Clinical Professor (Honorary),
Department of Ophthalmology
L & Visual Sciences, The Chinese
University of Hong Kong,
• Li Xiaorong
China
Director, Tianjin Medical
University Eye Hospital School
of Optometry & Eye Institute,
China
V
• Luis-Diaz Santana
Head of Ophthalmology, • Vivek Dave
Cambridge Consultants Consultant Vitreo Retina, Smt.
Kanuri Santhamma Centre
for Vitreo Retinal diseases, LV
Prasad Eye Institute, India
M
• Malcolm Ngiam
Deputy Managing Director, W
Essex Bio-Technology Ltd.
• Woohyok Chang
• Marcus Ang Doctor (M.D.), Founder &
Senior Consultant Owner, Chang's Retina Clinic
Ophthalmologist, Cornea &
Refractive Service, Singapore
National Eye Center, Singapore
• Michael Keyoung X
Managing Director CBC Group
• Xiaoyan Ding
(formerly C-Bridge Capital)
Director, Professor, Children's
• Mingguang He Center, Zhongshan Ophthalmic
Professor, The University of Center Sun Yet-sen University,
Melbourne, Australia China
N Z
• Noel Brennan • Zhou Xiang Tian
Clinical Research Fellow, Professor, School of
Myopia Control Platform, Ophthalmology & Optometry
Johnson & Johnson Vision and Eye Hospital, Wenzhou
Medical University, China
ASIAN RETINA VIRTUAL FORUM 2021 6SPONSORS: ASIAN FORUMS 2021
THANKS TO THE GENEROSITY OF OUR SPONSORS, THERE IS NO FEE FOR COMPANY
PRESENTATIONS AND DELEGATE REGISTRATION IS COMPLIMENTARY FOR EVERYONE.
ASIAN RETINA VIRTUAL FORUM 2021 7PLATINUM
Alcon is the global leader in eye care, dedicated to helping people see brilliantly. With
our 70-plus-year heritage, we are the largest eye care device company in the world – with
complementary businesses in Surgical and Vision Care. Being a truly global company, we
work in over 70 countries and serve patients in more than 140 countries. We have a long
history of industry firsts, and each year we commit a substantial amount in Research and
Development to meet customer needs and patient demands.
For more information, please visit www.alcon.com
As a global specialized company dedicated exclusively to ophthalmology, Santen brings
130-year history of scientific knowledge and organizational capabilities to research,
development, and commercialization of pharmaceutical, surgical, and OTC eye care
products. Headquartered in Osaka, Japan, Santen is the market leader in Japan for
prescription ophthalmic pharmaceuticals. With more than 4,000 employees worldwide,
Santen continues to grow its global presence across Asia, Europe, and North America,
providing innovative solutions in retina, glaucoma, uveitis, dry eye, ocular allergy and
infection to patients around the world.
For more information, please visit www.santen.com
ASIAN RETINA VIRTUAL FORUM 2021 8GOLD
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs,
develops, manufactures and markets implantable lenses for the eye with companion
delivery systems. These lenses are intended to provide visual freedom for patients,
lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are
foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens
used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes
the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted
to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL
go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates
manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau,
Switzerland.
For more information, please visit the Company’s website at www.staar.com
Helping Doctors Improve
Their Patients‘ Quality of Life.
ZEISS Medical Technology Business Group
Improving Quality of Life
ZEISS Medical Technology is proud
to support the Ophthalmology
Futures Asian Retina Forum
www.zeiss.comSILVER
Essilor International is the world’s leading ophthalmic optics company. For 170 years the Essilor
Group has put its expertise at the service of good vision in designing, manufacturing and
distributing quality products and services to eyecare professionals but also via innovative business
models. Essilor provides solutions to correct and protect the visual health of the 7.7 billion people
in the world as part of its mission “improving lives by improving sight”. A pioneer, innovation
continuously drives Essilor growth, with more than €200 million each year dedicated to research
and development. Essilor Group’s flagship brands include Varilux®, Crizal®, Transitions®,
Eyezen™, Xperio®, Foster Grant® and Bolon™. At Essilor we believe that people deserve the
right vision solutions to unleash the full potential of their life, every day, all life long. That belief
is anchored in the Group's mission.
For more information, please visit www.essilor.com
REGENXBIO Inc. is a leading clinical-
stage biotechnology company seeking
to improve lives through the curative
potential of gene therapy. Our gene
therapy product candidates are designed to
deliver functional genes to address genetic
defects in cells, enabling the production
of therapeutic proteins or antibodies that
are intended to impact disease. Through a
single administration, gene therapy could
potentially alter the course of disease The Medical Technology segment of ZEISS
significantly and deliver improved patient offers complete solutions to diagnose and
outcomes with long-lasting effects. We treat ophthalmic diseases. With a special
have developed a broad pipeline of focus on ophthalmology and ophthalmic
gene therapy programs using our NAV® surgery, the company supports healthcare
Technology Platform to address genetic professionals in setting new standards of
diseases through two modalities: AAV- care with proven medical technology and
mediated antibody delivery and monogenic broad application competence based on
gene replacement. We believe this platform cutting-edge innovations.
forms a strong foundation for our current
For more information, please visit
programs and with our ongoing research
www.zeiss.com/meditec/int/about-us.html
and development, we expect to continue to
expand the platform.
Please visit www.regenxbio.com
ASIAN RETINA VIRTUAL FORUM 2021 10BRONZE
GenSight Biologics is a clinical-stage biopharma company focused on developing and
commercializing innovative gene therapies for retinal neurodegenerative diseases and central
nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms,
the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in
patients suffering from blinding retinal diseases.
Developed as a treatment for Leber Hereditary Optic Neuropathy (LHON), GenSight Biologics’ lead
product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is currently in the review phase
of its registration process in Europe, and in Phase III to move forward to a BLA filing in the U.S.
Our second lead product candidate, GS030, combines gene therapy with optogenetics and is
currently in Phase I/II PIONEER to treat Retinitis Pigmentosa (RP).
For more information, please visit www.gensight-biologics.com
LENSAR®, Inc., the leader in next-generation
femtosecond cataract laser technology,
continues to focus on astigmatism with
Streamline® IV. This includes enhancements
Iveric Bio is a science-driven biopharmaceutical unique to LENSAR that are dedicated to help
company focused on the discovery and surgeons confidently manage astigmatism and
development of novel treatment options for optimize patient outcomes, for both toric IOLs
retinal diseases with significant unmet medical and arcuate incisions.
needs. The Company is currently developing
Enhancements include IntelliAxis Refractive
both therapeutic product candidates for
Capsulorhexis®, which incorporates lenticular
age-related retinal diseases and gene therapy
markings to guide precise and confident
product candidates for orphan inherited
toric IOL alignment, and wireless transfer
retinal diseases.
of preoperative data from multiple devices,
For more information on the Company, for seamless treatment planning. Iris
please visit www.ivericbio.com registration further contributes to accuracy
by automatically accounting for cyclotorsion.
The LENSAR Laser is revolutionizing the
surgeon’s ability to deliver great outcomes for
astigmatic patients.
Please visit www.lensar.com
Ora is the world's leading full-service ophthalmic research organization with offices in the
United States, United Kingdom, Australia, and Asia. For over 40 years, we have helped our clients
earn 48 product approvals. We support a wide array of organizations, from start-ups to global
pharmaceutical and device companies, to efficiently bring their new products from concept to
market. Ora's unique models, methodologies, and global regulatory strategies have been refined
and proven across thousands of global projects. We bring together the world's most extensive and
experienced team of ophthalmic experts to maximize the value of new product initiatives.
For more information, please visit www.oraclinical.com
ASIAN RETINA VIRTUAL FORUM 2021 11NEW INNOVATORS
LensGen®, a clinical stage ophthalmic medical device company headquartered in Irvine, California
has developed a disruptive fluid-optic intraocular lens (IOL) for treating cataracts and presbyopia.
With its innovative Juvene® IOL the company aims to bring to market this revolutionary device
designed to restore full range of vision with quality optics and improved safety due to the modular,
capsule filling design. The company is currently progressing through the IDE approval process and
is planning a large Series B Financing in early 2021 that will fund the company through approval of
the Juvene IOL pivotal FDA study.
For more information about the financing please contact Ramgopal Rao, CEO at rrao@lensgen.com
and visit www.lensgen.com
Radiance Therapeutics is developing a
next-generation beta therapy device for
ophthalmic scar prophylaxis. Re-Vana Therapeutics based in Northern
Ireland and Tampa Florida, is a specialty
This therapeutic modality has been
ocular therapeutic and drug delivery
validated in 4 randomised controlled
company focused on the development
trials from preeminent ophthalmic
of sustained release biologics and small
research teams. Applied topically at the molecules.
time of surgery, beta therapy has been
The Re-Vana platforms, which includes
shown to significantly improve glaucoma
EyeLief® and OcuLief® photocrosslinked
filtration surgery outcomes. The most
technologies, can deliver at least 6 months
recent of these studies reported odds
sustained delivery of large molecule
ratios indicating that beta therapy
biologics, including anti-VEGF therapies.
patients were five and a half times more
Re-Vana’s technology could also spur
likely to experience lower IOP at the end
a new generation of small molecule
of one year than patients treated with therapeutics enabling up to 12 months
antimetabolite mitomycin-C. delivery or greater.
For more information, please visit For more information, please visit
www.radiancetherapeutics.com www.revanatx.com
ASIAN RETINA VIRTUAL FORUM 2021 12SAVE THE DATES EURO VIRTUAL & HYBRID FORUMS European Forum HYBRID 2021 Thurs. 26 August Retina Forum Virtual 2021 Thurs. 09 September (Forums begin @ 8am CET / GMT +1) www.ophthalmology-futures.com
PROGRAMME COMMITTEE
Ike Ahmed | Division Head, Ophthalmology, Sir Peng Khaw | Professor of Glaucoma & of Ophthalmology, Quinze- Vingts National
Trilium Health Partners, Toronto, Canada. Ocular Healing, Director National Institute for Ophthalmology Hospital & Rothschild
Assistant Professor, University of Toronto, Health Research Biomedical Research Centre, Ophthalmology Foundation, Paris. Director,
Canada. Clinical Assistant Professor, University Moorfields Eye Hospital & UCL Institute of Institut de la Vision (Sorbonne Université,
of Utah, USA. Ophthalmology, London, UK. Inserm, CNRS, Paris).
Jorge Alio | Professor &Chairman of Shigeru Kinoshita | Professor & Chair, Chelvin Sng | Associate Professor,
Ophthalmology, Miguel Hernandez University, Department of Ophthalmology, Kyoto Department of Ophthalmology, National
Alicante, President, Vissum Corporation, Prefectural University of Medicine, Japan. University Hospital, Singapore.
Spain.
Richard Lindstrom | Founder & Attending Julian D. Stevens | Consultant Ophthalmic
Gerd Auffarth | Professor & Chairman, Surgeon: Minnesota Eye Consultants, Surgeon, Moorfields Eye Hospital, London,
Dept. of Ophthalmology, University Minneapolis, USA. Adjunct Professor Emeritus: UK.
of Heidelberg.Director, David J. Apple University of Minnesota, USA.
Donald Tan Tiang Hwee | Arthur Lim
International Laboratory for Ocular Pathology,
Boris Malyugin | Chief of Department of Professor, SNEC & Duke-NUS Medical School,
International Vision Correction Research
Cataract & Implant Surgery, Deputy Director Singapore. Partner & Senior Consultant
Centre, Heidelberg, Germany.
General, S. Fyodorov Eye Microsurgery Ophthalmic Surgeon, Eye & Retina Surgeons
Francesco Bandello | Full Professor & Complex State Institution, Moscow, Russia. (ERS), Camden Medical Centre, Singapore.
Chairman Department of Ophthalmology,
Prof David Spalton | Past-president, Marie-Jose Tassignon | Past Chief & Chair
University Vita-Salute, Ospedale San Raffaele
European Society of Cataract & Refractive Department of Ophthalmology Antwerp
of Milan, Italy.
Surgeons London, UK. University & University Hospital Antwerp,
David Chang | Altos Eye Physicians & Belgium.
Prof Dr Ingeborg Stalmans | Head of
Clinical Professor, University of California,
the Glaucoma Clinic, University Hospitals Adnan Tufail | Consultant Ophthalmologist,
San Francisco, USA.
UZ Leuven, Belgium. Head, Ophthalmology Moorfields Eye Hospital, London, UK.
Steve Charles | Founder & CEO, Charles Research Group, University KU Leuven, Professor, UCL Institute of Ophthalmology,
Retina Institute Clinical Professor of Belgium. London, UK.
Ophthalmology, University of Tennessee, USA.
Paulo Eduardo Stanga | London Vision Tien Yin Wong | Vice Dean, Academic &
Paul Chew | Professor of Ophthalmology, Clinic Retina Lead Consultant Ophthalmologist Clinical Development, Duke-NUS Medical
National University of Singapore, Singapore. & Vitreoretinal Surgeon. Professor of School, Singapore. Provost’s Chair Professor,
Ophthalmology & Retinal Regeneration, National University of Singapore. Deputy
Beatrice Cochener | Professor, Chairman,
University of Manchester, UK. Group CEO (Research & Education),
Ophthalmology Department, University
SingHealth, Singapore. Medical Director &
Hospital, Brest, France. Past-president, Paul Rosen | Consultant Ophthalmic
Senior Consultant Ophthalmologist, Singapore
European Society of Cataract & Refractive Surgeon, Oxford Eye Hospital, Oxford, UK.
National Eye Centre. Chair, Ophthalmology &
Surgeons.
José-Alain Sahel | Endowed Professor & Visual Sciences Academic Clinical Programme.
Jost Jonas | Professor of Ophthalmology, Chairman, Department of Ophthalmology, Chairman, Board of Directors, Singapore Eye
Medical Faculty Mannheim, University of University of Pittsburgh Medical Center, Research Institute, Singapore.
Heidelberg, Germany. Pittsburgh, USA. Professor of Ophthalmology,
Sorbonne Université. Chairman Departments
ORGANISING
ADVISORS COMMITTEE
Laurent Attias | Senior VP, Head of Malvina Eydelman | Director, Division of Keith Barton | Consultant Ophthalmologist,
Strategy, BD&L & Market Access, Alcon, USA. Ophthalmic & Ear, Nose & Throat Devices Moorfields Eye Hospital, London, UK.
ODE/CDRH/FDA, USA.
Eugene de Juan | Jean Kelly Stock Don Budenz | Professor & Chairman,
Distinguished Chair, Ophthalmology, ForSight Akira Kurokawa | Chairman. Santen Department of Ophthalmology, University of
Labs & University of California, Menlo Park, Pharmaceutical Co. North Carolina, USA.
California.
James Mazzo | JGlobal President Lea Pietrolongo | Operational Director,
Tom Dunlap | Founder, Dunlap Ophthalmic Devices, Carl Zeiss Meditec, USA. Ophthalmology Futures Forums, UK.
Ophthalmology Consulting, Board of
Naveed Siddiqi | Novo Ventures. Kuldev Singh | Professor of Ophthalmology
Directors, Advisory Boards.
& Director, Glaucoma Service, Stanford
University Medical Center, Palo Alto, USA.
Chelvin Sng | Associate Professor,
Department of Ophthalmology, National
ASIAN RETINA VIRTUAL FORUM 2021 14We Help People
See Brilliantly.
At Alcon, we aspire to lead the world in innovating life-changing vision
products because when people see brilliantly, they live brilliantly.
Each year our products touch the lives of millions of people living
with conditions like cataracts, retinal diseases, and refractive errors.
We offer the most complete line of ophthalmic surgical devices,
as well as a differentiated contact lens and lens care portfolio
to help patients see, look and feel their best.
At Alcon, we are at the forefront of innovation,
partnering with eye care professionals to bring
the gift of sight to more people around the world.
That’s been our legacy for more than 70 years—
and as the new Alcon, it’s what guides our
focus towards the brilliant future ahead.
Learn more at alcon.com
CONNECT WITH US!
@AlconEyeCare
@AlconCareers
@Alcon
@AlconLife
© 2021 Alcon Inc. 03/21 2103A164
ASIAN RETINA VIRTUAL FORUM 2021 15You can also read
